AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00209612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campt, Topotesin
Description: Day1,15 Y mg/m2, IV (in the vein)
Study NCT05932823 — intervention group
Intervention type: OTHER
Intervention: Laminary airflow
Description: A ventilation system that reduces the number of bacteria in the air compared to conventional ventilation.
Study NCT02808598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Cancer Clinical Trials Education Program
Description: The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation.
Study NCT02808598 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Breast Cancer Clinical Trials Education Program
Description: The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation.
Study NCT03029169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone i.v.
Description: Treatment
Study NCT04448756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants received M5049 50 milligram (mg) orally twice daily for 14 days.
Study NCT04448756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants received M5049 100 mg orally twice daily for 14 days.
Study NCT04448756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo tablets matched to M5049 daily for 14 days.
Study NCT01353456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patient will receive a loading dose of 1μg/kg (0.25ml/kg) intravenous dexmedetomidine over 10 minutes before induction, and then followed by continuous infusion at a rate of 0.5μg/kg/h (0.125ml/kg/h) until wound closure.
Study NCT01353456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Same volume as dexmedetomidine given
Study NCT03188354 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: PET scan with 18F-FDG as a tracer, taken both for primary staging and therapy assessment.
Study NCT03188354 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine
Description: PET scan with 18F-fluciclovine as a tracer, taken both for primary staging and response to therapy assessment.
Study NCT03188354 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: standard MRI
Description: clinical routine MRI examination, both for primary staging and response to therapy assessment.
Study NCT02710773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Backward Walking Treadmill Training
Description: The intervention will consist of 5 minutes of forward walking (warm-up phase), 10 minutes of backward walking (intervention phase) and 5 minutes of forward walking (cool-down phase). The session will be performed on a treadmill device. The backward training speed will be increase consecutively: during the week 1, the intervention will be performed at 0,8 km/h; during the week 2 the speed will be 1,0 km/h; finally, during the week 3 the speed will be increased till 1,2 km/h.
Study NCT02710773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Training
Description: The intervention will consist of 20 minutes of forward walking on a treadmill device.
Study NCT03740451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active mobilization of soft tissues
Description: This study will compare the effects of joint passive mobilization with the effects of soft tissue active mobilization on heart rate variability (as an indicator of autonomous regulation), psychological well-being (measured by the Ryff scale) and pain in patients with fibromyalgia.
Study NCT03740451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive mobilization
Description: This study will compare the effects of joint passive mobilization with the effects of soft tissue active mobilization on heart rate variability (as an indicator of autonomous regulation), psychological well-being (measured by the Ryff scale) and pain in patients with fibromyalgia.
Study NCT00437229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant (GW679769) Oral Tablets
Description: Casopitant (GW679769) tablets will be available as white, film-coated tablets containing 50 mg of GW679769 as the mesylate salt for oral administration.
Study NCT00437229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone will be available as 4 mg tablets for oral administration and injection for IV administration.
Study NCT00437229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Ondansetron for oral use will be available as 8 mg tablets to be taken with 240 milliliters (mL) of water on an empty stomach. For IV use, ondansetron 32 mg will be infused intravenously over a period of 15 minutes.
Study NCT01662765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: modified umbilectomy
Study NCT01662765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative
Description: this treatment will include conservative procedures under local anesthesia for patient comfort.
Study NCT01986426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-315 consecutive lesions
Description: Dose escalation:~Cohort 1: 2 mg twice per day (4 mg) Cohort 2: 3 mg twice per day (6 mg) Cohort 3: 4 mg twice per day (8 mg)
Study NCT01986426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-315
Description: Dose escalation:~Cohort 1: 3 mg per injection Cohort 2: 4 mg per injection Cohort 3: 5 mg per injection
Study NCT01986426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-315 + ipilimumab
Description: Cohort 1: 3 mg per injection + 3 mg/kg ipilumumab Cohort 2: 4 mg per injection + 3 mg/kg ipilumumab Cohort 3: 5 mg per injection + 3 mg/kg ipilumumab
Study NCT01986426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-315 + pembrolizumab
Description: Cohort 1: 3 mg per injection + 200 mg pembrolizumab Cohort 2: 4 mg per injection + 200 mg pembrolizumab Cohort 3: 5 mg per injection + 200 mg pembrolizumab
Study NCT02129699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab: 120 mg, s.c. every 3-4 weeks (in cycle 1 additional dose on day 8) until unacceptable toxicity, patient refusal or patient's death (max. 4 years 3 months).
Study NCT02129699 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: None, standard chemotherapy only
Description: Possible standard chemotherapies (3 weeks cycles, duration: 4 - 6 cycles):~Cisplatin 75 mg/m2 as an infusion on day 1 Gemcitabine 1250 mg/m2 as an infusion days 1 and 8 or Carboplatin AUC 5 as an infusion on day 1 Gemcitabine 1000 mg/m2 as an infusion days 1 and 8 or Cisplatin 75 mg/m2 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1 or Carboplatin AUC 5 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1
Study NCT06520917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Locator-Positioner (LOPO) Guide Device
Description: Patients underwent temporomandibular joint arthroscopy with the aid of the LOPO guide device
Study NCT02772458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dodecanoate acid and saline
Description: Test drink
Study NCT03957577 — intervention group
Intervention type: OTHER
Intervention: Prospective observational cohort study
Description: Prospective observational cohort study
Study NCT01349335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: tablet, 15 mg, Qd, for 7 days
Study NCT01349335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: tablet, 30 mg, Qd, 7 days
Study NCT01349335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: tablet, 30 mg, Qd, 7days.
Study NCT02150330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dehydroepiandrosterone (DHEAS)
Study NCT03342248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: access to the social network
Description: The development of a social network via a digital platform for carers of patients suffering from severe mental illness and study of the impact of its use on the health status of caregivers
Study NCT04597814 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT00160381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 10mg Tablet, oral Daily for 12 months
Study NCT00160381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 25 mg Tablet, oral Daily for 12 months
Study NCT00160381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral Daily for 12 months
Study NCT00315939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1)
Description: Integrated Biobehavioral Monitoring \& Feedback-1 (IBMF-1): a hand-held computer (HHC) was given to the subjects, programmed to estimate HbA1c, risk for hypoglycemia (Low BG Index), and glucose variability (Average Daily Risk Range) using previously published algorithms. The subjects were asked to carry the HHC and enter all their self-monitored blood glucose (SMBG) readings. The estimates of HbA1c were updated weekly, and the estimates of risk for hypoglycemia and glucose variability were updated at each SMBG entry. Detailed instructions were provided on the meaning of these different types of glucose feedback; the study staff was available to answer any questions.
Study NCT00315939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)
Description: Integrated Biobehavioral Monitoring \& Feedback-2 (IMBF-2) retains IMBF-1, but the HHC asked subjects to provide symptom ratings when blood glucose (BG) was low and at an equal number of matching euglycemic readings. From these data, the HHC estimated a set of potentially significant symptoms of hypoglycemia for each individual, using an iterative algorithm following a previously published symptom significance estimation procedure. The patient manual for the HHC program is provided in supplementary data of published manuscript.
Study NCT03312699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® quadrivalent
Description: IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by intramuscular (IM) injection into the deltoid muscle.
Study NCT03312699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High Dose
Description: High Dose IIV3 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
Study NCT03312699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluad
Description: Fluad vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
Study NCT03312699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaqta
Description: Vaqta vaccine will be administered as a 1 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
Study NCT03312699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhim Vi
Description: Typhim Vi vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
Study NCT03312699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vivotif
Description: One capsule is to be swallowed approximately 1 hour before a meal with a cold or luke-warm \[temperature not to exceed body temperature, e.g., 37 °C (98.6 °F)\] drink on alternate days, e.g., days 1, 3, 5 and 7.
Study NCT04112654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pressure laparoscopy
Description: Conventional pressure laparoscopy using conventional insufflator AirSeal®
Study NCT04112654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low pressure laparoscopy
Description: Low pressure laparoscopy using pressure-controlled insufflator AirSeal®
Study NCT04244487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation
Description: The modified procedure was implemented in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, divide the left lateral surface of the distal esophagus; (3) divide the posterior surface of the distal esophagus; (4) divide the anterior surface of the distal esophagus; (5) divide the lesser omental sac via the bottom right crural diaphragm; (6) transect en bloc the left gastric artery and vein and posterior gastric veins using a linear laparoscopic vascular stapler; (7) find the right crural diaphragm by dividing a small portion of the hepatogastric ligament at the left lateral esophagogastric junction; and (8) via the surface of the right crural diaphragm, divide the right lateral surface of the distal esophagus.~After the procedure of laparoscopic azygoportal disconnection, intraoperative endoscopic variceal ligation was made if the diameter of the esophageal varices was >5 mm.
Study NCT04342832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon ablation
Description: If a patient is randomized to early invasive treatment, the ablation is performed within 3 months by an experienced cardiac electrophysiologist using CE-certified equipment. Via the femoral vein a guiding catheter is advanced through the inferior vena cava to the right atrium and into the left atrium via transseptal puncture. Then, the cryoballoon is advanced, inflated, and placed against one of the four PVs. PV occlusion is assessed by selective contrast injection. When adequate PV antral seal is confirmed, ablation of the tissue in contact with the balloon is performed using pressurized liquid nitrous oxide. The cold inflated balloon thus creates circular lesions around the PV. The balloon and tissue interface are then allowed to reach normal temperatures. Depending on local practice, the freeze-thaw cycle may be repeated twice. Electrical isolation is assessed and when it is confirmed, the next PV is treated in the same way. The procedure ends when all PV's are isolated.
Study NCT02847741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: patient's routine care
Description: Interview by psychiatrists, questionnaires, blood analysis
Study NCT00301522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation
Description: Paclitaxel-Eluting Coronary Stent, Slow-Formulation
Study NCT00301522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Express2
Description: Coronary Stent System
Study NCT03912194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral withdrawal regulation strategies
Description: Participants will generate and refine individualized withdrawal regulation strategies with the aid of a therapist
Study NCT03912194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive-behavioral withdrawal regulation strategies
Description: Participants will generate and refine individualized withdrawal regulation strategies with the aid of a therapist
Study NCT00231153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan 1% gel
Description: Patients randomized to omiganan group will receive an application of omiganan gel around the catheter insertion site following catheter insertion. Every 3 days the dressing will be changed and patients will receive a new application of Omiganan 1% gel.
Study NCT00231153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine 10%
Description: All CVC sites will be disinfected using a 10% povidone-iodine scrub for a minimum of 2 minutes prior to catheter insertion. Patients randomized to the povidone-iodine group will receive no further antiseptic treatment after catheter insertion until dressing changes. Every three days the dressing will be changed and the catheter site will be sterilized with povidone-iodine.
Study NCT04111432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Concomitant administration of EV71vaccine with EPI vaccines
Description: The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.# the MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.
Study NCT04111432 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Single injection of EPI vaccine
Description: The MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.
Study NCT04111432 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EV71 Vaccine only
Description: The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
Study NCT03912194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation strategies
Description: Participants will generate and refine relaxation techniques with the aid of a therapist
Study NCT03912194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: early withdrawal exposure
Description: Exposure to the first 4 hours of abstinence across 4 separate sessions
Study NCT03912194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: early withdrawal exposure
Description: Exposure to the first 4 hours of abstinence across 4 separate sessions
Study NCT03250715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: For application of the LLLT in the quadriceps muscle the patient will be in dorsal decubitus, with the legs extended and will be defined by the palpation of the muscle belts six points of application: two points in the distal region of the vastus medialis muscle, two points of the distal region of the vastus lateral muscle and two points of the central region of the rectus femoris muscle. For the application of LLLT in the gastrocnemius muscle the patient will remain in the supine position, but will be oriented to keep the hips and knees flexed at 90º and 45º respectively. Two application points will be defined, one in the lateral ventricle and the other in the medial ventricle, but both in the distal region of the muscle.
Study NCT03254797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepping training with feedback
Description: Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
Study NCT03254797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stepping training without feedback
Description: Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
Study NCT02628873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyCoSy
Description: Saline infused sonogram in which air bubbles are delivered via the FemVue saline air device in order to evaluate the patency (openness) of the fallopian tubes
Study NCT01619280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: Each subject will receive one of five possible dosages of nebulized sodium nitroprusside. The dosage will be determined by the 3 + 3 dose escalation design. Only a maximum of six patients will be given a particular dosage. Arterial blood gases will be drawn at 0 min, 15 min, 30 min and 45 min during nebulized sodium nitroprusside administration. Vitals signs will be recorded every five minutes. No changes to ventilator settings or vasopressor dosage or fluid administration will be allowed.
Study NCT04680494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate intensity physical exercise
Study NCT04680494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity physical exercise
Study NCT04680494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rest
Study NCT02378454 — intervention group
Intervention type: DEVICE
Intervention: Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D
Description: Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
Study NCT00517777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure ventilation
Description: nighttime
Study NCT00517777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary and life style recommendations
Study NCT00517777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary and life style recommendations